Showing 2471-2480 of 6036 results for "".
- Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Reporthttps://modernod.com/news/nordic-pharmas-lacrifill-canalicular-gel-highlighted-in-landmark-dews-iii-report/2482927/Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and O
- Kate Flannery Teams Up with Contact Lens Institute to Promote 'The EASY Way' for Contact Lens Healthhttps://modernod.com/news/kate-flannery-teams-up-with-contact-lens-institute-to-promote-the-easy-way-for-contact-lens-health/2482914/Comedian Kate Flannery has partnered with the Contact Lens Institute (CLI) to amplify a new campaign titled 'The EASY Way,' with the goal of communicating safe, effective soft contact lens wear-and-care routines.
- Vision Advocates Rally to Defend National Eye Institute from Funding Cuts and Consolidation Threatshttps://modernod.com/news/vision-advocates-rally-to-defend-national-eye-institute-from-funding-cuts-and-consolidation-threats/2482913/Vision science and eye care organizations are mobilizing efforts to combat proposals circulating in Washington to slash federal vision funding and consolidate the National Eye Institute (NEI) into a broader institute on brain and dental research.
- Lenz Therapeutics Receives FDA Approval of VIZZ for the Treatment of Presbyopiahttps://modernod.com/news/lenz-therapeutics-receives-fda-approval-of-vizz-for-the-treatment-of-presbyopia/2482912/A new, first-of-its kind presbyopia drop will soon be available in the US as the FDA approved Lenz Therapeutics' VIZZ (aceclidine ophthalmic solution) 1.44%. Expected to be broadly available in the fourth quarter of 2025, VIZZ is the first and only FDA-approved aceclidine-based
- Viridian Therapeutics Enters Collaboration to Develop and Commercialize Thyroid Eye Disease Therapies in Japanhttps://modernod.com/news/viridian-therapeutics-enters-collaboration-to-develop-and-commercialize-thyroid-eye-disease-therapies-in-japan/2482910/Viridian Therapeutics announced an exclusive collaboration and license agreement with Kissei Pharmaceutical to develop and commercialize investigatonal drug candidates veligrotug and VRDN-003 in Japan. Both veligrotug and
- Boehringer Ingelheim and Re-Vana Therapeutics Collaborate to Develop Long-Acting Ophthalmic Therapieshttps://modernod.com/news/boehringer-ingelheim-and-re-vana-therapeutics-announce-collaboration-to-develop-long-acting-ophthalmic-therapies/2482905/Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration and license agreement designed to accelerate the development of first-in-class extended-release therapies for vision-threatening eye diseases.
- Sanofi’s Intravitreal Gene Therapy Earns FDA Fast Track Designation for Geographic Atrophyhttps://modernod.com/news/sanofis-intravitreal-gene-therapy-earns-fda-fast-track-designation-for-geographic-atrophy/2482888/The FDA has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The fast track designation process aims to facilitate the developm
- ViaLase Announces Strategic Leadership Transitionshttps://modernod.com/news/vialase-announces-strategic-leadership-transitions/2482876/ViaLase announced changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to
- Alcon to Acquire LumiThera, Maker of Photobiomodulation Device for the Treatment of Dry AMDhttps://modernod.com/news/alcon-to-acquire-lumithera-maker-of-photobiomodulation-device-for-the-treatment-of-dry-amd/2482873/In a move to bolster is vitreoretinal surgery portfolio, Alcon announced its intention to acquire LumiThera and its photobiomodulation (PBM) device for the treatment of dry early and intermediate dry AMD.
- Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi Inc.https://modernod.com/news/eyenovia-announces-rebranding-and-corporate-name-change-to-hyperion-defi-inc/2482871/Eyenovia announced a rebrand to Hyperion DeFi Inc., signaling a pivot toward decentralized finance. The rebranding reflects Hyperion DeFi’s cryptocurrency treasury reserve strategy, centered around HYPE, the native token of the Hyperliquid block